Charles River Laboratories International Inc
NYSE:CRL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
178.58
273.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Charles River Laboratories International Inc
Charles River Laboratories International Inc
Cost of Revenue
Charles River Laboratories International Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Charles River Laboratories International Inc
NYSE:CRL
|
Cost of Revenue
-$2.6B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-12%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Cost of Revenue
-$25.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-11%
|
|
|
Danaher Corp
NYSE:DHR
|
Cost of Revenue
-$8.6B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
0%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Cost of Revenue
-$1.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Cost of Revenue
-$2.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-11%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Cost of Revenue
-$9.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-10%
|
|
Charles River Laboratories International Inc
Glance View
Charles River Laboratories International Inc. is a leading provider of essential research services and products that support the global clinical development of new drugs. Founded in 1947, the company has evolved from a small laboratory in Massachusetts to a formidable player within the biotech and pharmaceutical sectors. Its comprehensive suite of offerings includes preclinical and clinical laboratory services, along with a range of research models that help organizations like pharmaceutical companies and academic institutions navigate the complexities of drug development. By partnering with clients from early-stage discovery through to advanced trials, Charles River plays a pivotal role in bringing innovative therapies to market while maintaining a strong commitment to animal welfare and ethical research practices. As an investment opportunity, Charles River Laboratories stands out due to its solid financial performance, buoyed by a strategic focus on expanding its capabilities and services. The company has shown robust revenue growth over the years, driven by increasing demand for outsourced laboratory services, especially as the biotech landscape becomes more competitive. With a dedicated management team and a continual investment in technology and infrastructure, Charles River is well-positioned to capitalize on the rising need for more efficient drug development processes. Investors can take confidence from the company's strong market presence, consistent execution, and strategic acquisitions that enhance its service offerings, making it a compelling choice for those looking to invest in the healthcare space.
See Also
What is Charles River Laboratories International Inc's Cost of Revenue?
Cost of Revenue
-2.6B
USD
Based on the financial report for Sep 28, 2024, Charles River Laboratories International Inc's Cost of Revenue amounts to -2.6B USD.
What is Charles River Laboratories International Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-12%
Over the last year, the Cost of Revenue growth was 2%. The average annual Cost of Revenue growth rates for Charles River Laboratories International Inc have been -7% over the past three years , -10% over the past five years , and -12% over the past ten years .
You don't have any saved screeners yet
